Stattin Martin, Hagen Stefan, Ahmed Daniel, Smretschnig Eva, Frommlet Florian, Krepler Katharina, Ansari-Shahrezaei Siamak
Karl Landsteiner Institute of Retinal Research and Imaging, Vienna 1030, Juchgasse 25, Austria.
Department of Ophthalmology, Rudolf Foundation Hospital, Vienna 1030, Juchgasse 25, Austria.
J Ophthalmol. 2020 Feb 17;2020:8491712. doi: 10.1155/2020/8491712. eCollection 2020.
To evaluate normalized short-wavelength fundus autofluorescence (SW-FAF) imaging changes over time as a predictive parameter for the retinal pigment epithelium (RPE) function in eyes compromised by acute central serous chorioretinopathy (CSCR) after indocyanine green angiography-guided verteporfin (Visudyne®, Novartis Pharma, Basel, Switzerland) photodynamic therapy (PDT) with a half-fluence rate (25 J/cm).
Quantitative data of SW-FAF grey values (SW-FAF GV) from a 350 m (SW-350) and 1200 m (SW-350) and 1200 -test was calculated to explore the differences of SW-350 and SW-1200 between one month and the long-term follow-up.
Mean differences (95% CI) in SW-FAF GV between 1 month and 7 years after half-fluence PDT were 0.07 ± 0.11 for SW-350 ([95% CI: -0.002; 0.14], =0.06) and 0.11 ± 0.15 for SW-1200 ([95% CI: 0.01; 0.21], =0.06) and 0.11 ± 0.15 for SW-1200 ([95% CI: 0.01; 0.21], =0.06) and 0.11 ± 0.15 for SW-1200 ([95% CI: 0.01; 0.21], =0.06) and 0.11 ± 0.15 for SW-1200 ([95% CI: 0.01; 0.21].
After 7 years, normalized SW-FAF GV were significantly lower in eyes with resolved acute CSCR treated with reduced-fluence PDT compared to the follow-up after 1 month without correlation to explicit pattern changes or structural damages. Half-fluence PDT remains a safe and considerable treatment option in acute CSCR.
评估在吲哚菁绿血管造影引导下，采用半光通量率（25 J/cm）的维替泊芬（Visudyne®，诺华制药，瑞士巴塞尔）光动力疗法（PDT）治疗急性中心性浆液性脉络膜视网膜病变（CSCR）后，归一化短波长眼底自发荧光（SW-FAF）成像随时间的变化，以此作为视网膜色素上皮（RPE）功能的预测参数。
计算来自350 m（SW-350）和1200 m（SW-1200）测试的SW-FAF灰度值（SW-FAF GV）的定量数据，以探究1个月与长期随访之间SW-350和SW-1200的差异。
半光通量PDT后1个月至7年，SW-350的SW-FAF GV平均差异（95% CI）为0.07±0.11（[95% CI：-0.002；0.14]，P = 0.06），SW-1200为0.11±（此处原文重复，疑有误，按正确理解翻译）0.15（[95% CI：0.01；0.21]，P = 0.06）。
7年后，与1个月随访相比，接受低光通量PDT治疗且急性CSCR已缓解的眼中，归一化SW-FAF GV显著降低，且与明确的模式变化或结构损伤无关。半光通量PDT在急性CSCR中仍然是一种安全且值得考虑的治疗选择。
